Annual Report 2020

Operating programme

Amount % on category % on total income

Grants

375000    
  AbbVie 30000 8% 3.71%
  Astra Zeneca 30000 8% 3.71%
  Boehringer Ingelheim 30000 8% 3.71%
  Chiesi 30000 8% 3.71%
  DBV Technologies 30000 8% 3.71%
  GlaxoSmithKline 30000 8% 3.71%
  Hoffmann Roche 30000 8% 3.71%
  MSD 15000 4% 1.85%
  Novartis 30000 8% 3.71%
  OM Vifor Pharma 30000 8% 3.71%
  Pfizer 30000 8% 3.71%
  Regeneron 30000 8% 3.71%
  Sanofi Genzyme 30000 8% 3.71%

Honoraria for advisors

4269    
  Honoraria for advisors 4269   0.53%

Membership fees

10000    
  Membership fees 10000   1.24%

Project programme

Amount % on category % on total income

EFA projects

449915   46.27%
  Capacity Building Astra Zeneca 75000 16.67% 9.27%
  Capacity Building Chiesi 15000 3.33% 1.85%
  Capacity Building GlaxoSmithKline 10000 2.22% 1.24%
  Capacity Building Novartis 50000 11.11% 6.18%
  Showleadership AbbVie 25000 5.56% 3.09%
  Showleadership Astra Zeneca 25000 5.56% 3.09%
  Showleadership Boehringer Ingelheim 25000 5.56% 3.09%
  Showleadership Chiesi 25000 5.56% 3.09%
  Showleadership GlaxoSmithKline 25000 5.56% 3.09%
  Showleadership Sanofi/Regeneron 25000 5.56% 3.09%
  Showleadership deferred income 2019 to 2020 16581 3.69% 2.05%
  Atopic Eczema Awareness Day AbbVie 53333 11.85% 6.59%
  Atopic Eczema Awareness Day Sanofi/Regeneron 80000 17.78% 9.89%
  Deferred income 2020 for EFA Projects 2021 -75650 -16.81% -9.35%

EU projects

18870   2.33%
  3TR 6376 33.79% 0.79%
  CURE 6506 34.48% 0.80%
  Immuniverse 5988 31.73% 0.74%

Transfer to reserves

100000    
  Transfert to social liability 50000    
  Transfer to organisation reserves 50000